LeonaBio (LONA) Long-Term Deferred Tax (2022 - 2023)
LeonaBio's (LONA) quarterly Long-Term Deferred Tax came in at $25.2 million in Q4 2023, up 135.51% year-on-year from $10.7 million in Q4 2022, and up 135.51% on a QoQ basis from $10.7 million in Q4 2022.
LeonaBio (LONA) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
LeonaBio (LONA) has 2 years of Long-Term Deferred Tax data on file, last reported at $25.2 million in Q4 2023.
- On a quarterly basis, Long-Term Deferred Tax rose 135.51% year-over-year to $25.2 million in Q4 2023; TTM through Dec 2023 was $25.2 million, a 135.51% increase from a year earlier, with the FY2023 full-year figure at $25.2 million, up 135.51% from the prior year.
- Long-Term Deferred Tax for Q4 2023 stood at $25.2 million, up from $10.7 million in the prior quarter.
- Over the last five years, Long-Term Deferred Tax for LONA reached as high as $25.2 million in Q4 2023 and fell as low as $10.7 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | LeonaBio | 138.33 Mn | 70.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 25.20 Mn |
| Dec 31, 2022 | 10.70 Mn |